Evidence map›Paper›PMID 33167505›Full record

ArticleMolecules (Basel, Switzerland)2020

Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors.

Hyo Jeong Kim, Hwani Ryu, Jie-Young Song, Sang-Gu Hwang, Shivakumar S Jalde, Hyun-Kyung Choi, Jiyeon Ahn

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hyo Jeong KimDivision of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Hwani RyuDivision of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Jie-Young SongDivision of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.ORCID 0000-0002-5769-3886
Sang-Gu HwangDivision of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.
Shivakumar S JaldeDepartment of Medicinal Chemistry, Jungwon University, Goesan 28024, Korea.ORCID 0000-0001-6718-4164
Hyun-Kyung ChoiDepartment of Medicinal Chemistry, Jungwon University, Goesan 28024, Korea.
Jiyeon AhnDivision of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Seoul 01812, Korea.ORCID 0000-0002-4098-7634
Korea Institute of Radiological and Medical Sciences · KRJungwon University · KRKorea University · KR

Funding

Korean government Ministry of Science and ICT 2019R1A2C1009238; 50531-2020; 50538-2020
6 · The paper itself

Abstract

Internal tandem duplication (ITD) of FMS-like tyrosine kinase 3 (FLT3) is the most common mutation in patients with acute myeloid leukemia (AML). FLT3-ITD

Indexed as

AminesAnimalsAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCell SurvivalDNA DamageDNA Repairfms-Like Tyrosine Kinase 3HL-60 CellsHumansInhibitory Concentration 50Leukemia, Myeloid, AcuteMiceMice, Inbred BALB CAminesAntineoplastic AgentsFLT3 protein, humanFlt3 protein, mousefms-Like Tyrosine Kinase 3OxazolesPARP1 protein, humanParp1 protein, mousePoly (ADP-Ribose) Polymerase-1Protein Kinase Inhibitorsacute myeloid leukemiacombination therapyDNA damage repairFLT3 inhibitorPARP1 inhibitor

Identifiers

PMID33167505
PMCPMC7663913
OpenAlexW3097752357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.